Acorah Software Products - Accounts Production 16.5.460 false true false 1 March 2024 28 February 2025 28 February 2025 15462784 Mrs Polytimi Ellina Mr Takaaki Matsuoka Hongkies Limited iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 15462784 2024-02-29 15462784 2025-02-28 15462784 2024-03-01 2025-02-28 15462784 frs-core:CurrentFinancialInstruments 2025-02-28 15462784 frs-core:Non-currentFinancialInstruments 2025-02-28 15462784 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2025-02-28 15462784 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2024-03-01 2025-02-28 15462784 frs-core:LandBuildings frs-core:LeasedAssetsHeldAsLessee 2024-02-29 15462784 frs-core:PlantMachinery 2025-02-28 15462784 frs-core:PlantMachinery 2024-03-01 2025-02-28 15462784 frs-core:PlantMachinery 2024-02-29 15462784 frs-core:SharePremium 2025-02-28 15462784 frs-core:ShareCapital 2025-02-28 15462784 frs-core:RetainedEarningsAccumulatedLosses 2025-02-28 15462784 frs-bus:PrivateLimitedCompanyLtd 2024-03-01 2025-02-28 15462784 frs-bus:FilletedAccounts 2024-03-01 2025-02-28 15462784 frs-bus:SmallEntities 2024-03-01 2025-02-28 15462784 frs-bus:AuditExempt-NoAccountantsReport 2024-03-01 2025-02-28 15462784 frs-bus:SmallCompaniesRegimeForAccounts 2024-03-01 2025-02-28 15462784 frs-bus:Director1 2024-03-01 2025-02-28 15462784 frs-bus:Director2 2024-03-01 2025-02-28 15462784 frs-bus:CompanySecretary1 2024-03-01 2025-02-28 15462784 frs-countries:EnglandWales 2024-03-01 2025-02-28
Registered number: 15462784
Helene Therapeutics Limited
Financial Statements
For The Year Ended 28 February 2025
Helene Therapeutics Limited
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—4

Page 1
Helene Therapeutics Limited
Balance Sheet
As At 28 February 2025
Balance Sheet
Registered number: 15462784

| 2025
--- | ---
| Notes | £ | £
FIXED ASSETS
Tangible Assets | 4 |  | 737,372
|  |  | 737,372
CURRENT ASSETS
Debtors | 5 | 603,654 |
Cash at bank and in hand |  | 1,777,581 |
|  | 2,381,235 |
Creditors: Amounts Falling Due Within One Year | 6 | (601,650 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 1,779,585
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 2,516,957
Creditors: Amounts Falling Due After More Than One Year | 7 |  | (940,637 )
NET ASSETS |  |  | 1,576,320
CAPITAL AND RESERVES
Called up share capital | 8 |  | 12,500
Share premium account |  |  | 2,497,500
Profit and Loss Account |  |  | (933,680 )
SHAREHOLDERS' FUNDS |  |  | 1,576,320

Page 1
Page 2
Helene Therapeutics Limited
Balance Sheet (continued)
As At 28 February 2025
For the year ending 28 February 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Mr Takaaki Matsuoka Director
5 November 2025

The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Helene Therapeutics Limited
Notes to the Financial Statements
For The Year Ended 28 February 2025
Notes to the Financial Statements
1. General Information
Helene Therapeutics Limited is a private company, limited by shares, incorporated in England & Wales, registered number 15462784 . The registered office is 15 Lavey House, 10 Belgrave Road, London, HA0 1AG.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Leasehold | 10% Straight Line
Plant & Machinery | 20% Reducing Balance

2.3. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 4
4
4. Tangible Assets

| Land & Property
--- | ---
| Leasehold | Plant & Machinery | Total
| £ | £ | £
Cost
As at 1 March 2024 | - | - | -
Additions | 662,011 | 181,598 | 843,609
As at 28 February 2025 | 662,011 | 181,598 | 843,609
Depreciation
As at 1 March 2024 | - | - | -
Provided during the period | 70,055 | 36,182 | 106,237
As at 28 February 2025 | 70,055 | 36,182 | 106,237
Net Book Value
As at 28 February 2025 | 591,956 | 145,416 | 737,372
As at 1 March 2024 | - | - | -

Page 3
Page 4
Helene Therapeutics Limited
Notes to the Financial Statements (continued)
For The Year Ended 28 February 2025
5. Debtors

| 2025
--- | ---
| £
Due within one year
Other debtors | 198,654
Due after more than one year
Other debtors | 405,000
| 603,654

6. Creditors: Amounts Falling Due Within One Year

| 2025
--- | ---
| £
Trade creditors | 182,264
Other creditors | 414,542
Taxation and social security | 4,844
| 601,650

7. Creditors: Amounts Falling Due After More Than One Year

| 2025
--- | ---
| £
Other creditors | 940,637

8. Share Capital

| 2025
--- | ---
| £
Allotted, Called up and fully paid | 12,500

Page 4